VentriPoint Diagnostics Ltd. (CVE:VPT) Director Robert Hodgkinson Purchases 75,000 Shares

VentriPoint Diagnostics Ltd. (CVE:VPT) Director Robert Hodgkinson bought 75,000 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were purchased at an average cost of C$0.21 per share, for a total transaction of C$15,900.00.

Robert Hodgkinson also recently made the following trade(s):

• On Wednesday, April 24th, Robert Hodgkinson acquired 21,000 shares of VentriPoint Diagnostics stock. The stock was purchased at an average price of C$0.21 per share, for a total transaction of C$4,410.00.
• On Thursday, April 18th, Robert Hodgkinson acquired 36,500 shares of VentriPoint Diagnostics stock. The stock was purchased at an average price of C$0.21 per share, for a total transaction of C$7,774.50.

VentriPoint Diagnostics Price Performance

VentriPoint Diagnostics stock opened at C$0.21 on Thursday. VentriPoint Diagnostics Ltd. has a 12 month low of C$0.12 and a 12 month high of C$0.36. The company has a current ratio of 2.06, a quick ratio of 6.67 and a debt-to-equity ratio of 32.61. The business’s 50 day simple moving average is C$0.25 and its 200 day simple moving average is C$0.24. The company has a market cap of C$32.93 million, a price-to-earnings ratio of -7.00 and a beta of 0.39.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements.